NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization21.19 mln
Float11.85 mln
Earnings Date08/17/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
90
/ 100
Top performer
Debt / Equity
0.35
Low leverage
ROE
-144
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Cocrystal Pharma is a US-based drug development company working to create new treatments for serious viral infections, including influenza, norovirus, coronaviruses, and hepatitis C. The company uses advanced structural biology methods to design its medicines, with several candidates currently in clinical trials. It works alongside partners such as Merck and Kansas State University to advance its research pipeline.
